Panel of experts will discuss the persistent cardiovascular risk among patients with a history of ASCVD events and the importance of LDL-lowering in secondary prevention. Experts also evaluate current and emerging PCSK9-targeting therapies and share practical strategies for integrating PCSK9 inhibition into post-event lipid management to achieve optimal LDL-C control and improve long-term outcomes.
This program brings together leading experts to discuss evolving strategies for reducing recurrent cardiovascular risk in patients with ASCVD, emphasizing the importance of cumulative LDL-C exposure and the need for earlier, more intensive lipid lowering. The panel explores current guidelines, emerging data from recent trials, and practical approaches to integrating PCSK9-targeting therapies to improve long-term adherence, access, and outcomes in secondary prevention
This program brings together leading experts to discuss evolving strategies for reducing recurrent cardiovascular risk in patients with ASCVD, emphasizing the importance of cumulative LDL-C exposure and the need for earlier, more intensive lipid lowering. The panel explores current guidelines, emerging data from recent trials, and practical approaches to integrating PCSK9-targeting therapies to improve long-term adherence, access, and outcomes in secondary prevention
Experts discuss barriers to effective lipid-lowering therapy, emphasizing the need for systematic approaches and early combination treatments to improve patient outcomes.
Explore the mechanisms and differences between PCSK9 inhibitors, including monoclonal antibodies and siRNA, in lowering LDL cholesterol effectively.
Discover the critical importance of early LDL lowering with PCSK9 inhibitors to reduce cardiovascular risks and improve patient outcomes.
A groundbreaking trial reveals the effectiveness of aggressive LDL lowering in high-risk patients, showcasing significant improvements in cholesterol management.
Healthcare professionals explore effective strategies for LDL cholesterol management, emphasizing patient involvement and innovative therapies for optimal outcomes.
Healthcare professionals discuss strategies for effectively lowering LDL cholesterol in patients post-cardiac events, emphasizing early intervention and tailored therapies.
Experts discuss innovative strategies for managing statin-intolerant patients, highlighting new therapies and the importance of individualized care.
Experts discuss innovative strategies for managing statin-intolerant patients, highlighting new therapies and the importance of individualized care.
Experts discuss evolving strategies in atherosclerosis prevention, emphasizing early intervention and the importance of cholesterol monitoring for better patient outcomes.
Explore the barriers to PCSK9 inhibitors, their underuse, and how addressing misconceptions can enhance patient outcomes in cholesterol management.
Engaging patients in their treatment journey enhances adherence to therapies, ultimately improving health outcomes and managing cholesterol effectively.
Experts discuss groundbreaking innovations in cardiovascular disease prevention, highlighting personalized medicine and new therapies for effective treatment.
